Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398:535–54.
Google Scholar
Cavalheri V, Granger CL. Exercise training as part of lung cancer therapy. Respirology. 2020;25:80–87.
Google Scholar
Relli V, Trerotola M, Guerra E, Alberti S. Abandoning the notion of non-small cell lung cancer. Trends Mol Med. 2019;25:585–94.
Google Scholar
Friedlaender A, Addeo A, Russo A, Gregorc V, Cortinovis D, Rolfo CD, Targeted therapies in early stage NSCLC: Hype or hope? Int J Mol Sci, 2020. 21:6329.
Bauer AK, Umer M, Richardson VL, Cumpian AM, Harder AQ, Khosravi N et al. Requirement for MUC5AC in KRAS-dependent lung carcinogenesis. JCI Insight, 2018. 3:e120941.
Reck M, Carbone DP, Garassino M, Barlesi F. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol. 2021;32:1101–10.
Google Scholar
Passaro A, Peters S. Setting the benchmark for KRAS(G12C) -mutated NSCLC. N Engl J Med. 2022;387:180–3.
Google Scholar
Liu C, Zheng S, Wang Z, Wang S, Wang X, Yang L, et al. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer. Cancer Commun. 2022;42:828–47.
Google Scholar
Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 2019;19:495–509.
Google Scholar
Dong L, Lu D, Chen R, Lin Y, Zhu H, Zhang Z, et al. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma. Cancer Cell. 2022;40:70–87 e15.
Google Scholar
Sidaway P. Sotorasib effective in KRAS-mutant NSCLC. Nat Rev Clin Oncol. 2021;18:470.
Google Scholar
Ricciuti B, Alessi JV, Elkrief A, Wang X, Cortellini A, Li YY, et al. Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS(G12D)-mutated non-small-cell lung cancer. Ann Oncol. 2022;33:1029–40.
Google Scholar
Wang S, Lv H, Zhou F. AARS1 and AARS2, the L-lactate sensors and universal lactyltransferases. Sci Bull. 2025;70:1547–9.
Google Scholar
Zong Z, Ren J, Yang B, Zhang L, Zhou F. Emerging roles of lysine lactyltransferases and lactylation. Nat Cell Biol. 2025;27:563–74.
Google Scholar
Zong Z, Xie F, Wang S, Wu X, Zhang Z, Yang B, et al. Alanyl-tRNA synthetase, AARS1, is a lactate sensor and lactyltransferase that lactylates p53 and contributes to tumorigenesis. Cell. 2024;187:2375–92 e33.
Google Scholar
Ju J, Zhang H, Lin M, Yan Z, An L, Cao Z, et al. The alanyl-tRNA synthetase AARS1 moonlights as a lactyltransferase to promote YAP signaling in gastric cancer. J Clin Invest, 2024. 134:e174587.
Li X, Zhang C, Mei Y, Zhong W, Fan W, Liu L, et al. Irinotecan alleviates chemoresistance to anthracyclines through the inhibition of AARS1-mediated BLM lactylation and homologous recombination repair. Signal Transduct Target Ther. 2025;10:214.
Google Scholar
Shan G, Bian Y, Sui Q, Liang J, Ren S, Pan B, et al. Ferroptosis-induced SUMO2 lactylation counteracts ferroptosis by enhancing ACSL4 degradation in lung adenocarcinoma. Cell Discov. 2025;11:81.
Google Scholar
Zhan P, Wang Y, Zhao S, Liu C, Wang Y, Wen M, et al. FBXW7 negatively regulates ENO1 expression and function in colorectal cancer. Lab Invest. 2015;95:995–1004.
Google Scholar
Deng T, Shen P, Li A, Zhang Z, Yang H, Deng X, et al. CCDC65 as a new potential tumor suppressor induced by metformin inhibits activation of AKT1 via ubiquitination of ENO1 in gastric cancer. Theranostics. 2021;11:8112–28.
Google Scholar
Nagaraj R, Sharpley MS, Chi F, Braas D, Zhou Y, Kim R, et al. Nuclear localization of mitochondrial TCA cycle enzymes as a critical step in mammalian zygotic genome activation. Cell. 2017;168:210–223 e11.
Google Scholar
Arnold PK, Jackson BT, Paras KI, Brunner JS, Hart ML, Newsom OJ, et al. A non-canonical tricarboxylic acid cycle underlies cellular identity. Nature. 2022;603:477–81.
Google Scholar
Li W, Long Q, Wu H, Zhou Y, Duan L, Yuan H, et al. Nuclear localization of mitochondrial TCA cycle enzymes modulates pluripotency via histone acetylation. Nat Commun. 2022;13:7414.
Google Scholar
Mao Y, Zhang J, Zhou Q, He X, Zheng Z, Wei Y, et al. Hypoxia induces mitochondrial protein lactylation to limit oxidative phosphorylation. Cell Res. 2024;34:13–30.
Google Scholar
Romero R, Sayin VI, Davidson SM, Bauer MR, Singh SX, LeBoeuf SE, et al. Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nat Med. 2017;23:1362–8.
Google Scholar
Gillette MA, Satpathy S, Cao S, Dhanasekaran SM, Vasaikar SV, Krug K, et al. Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma. Cell. 2020;182:200–225 e35.
Google Scholar
Qian Y, Galan-Cobo A, Guijarro I, Dang M, Molkentine D, Poteete A, et al. MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma. Cancer Cell. 2023;41:1363–1380 e7.
Google Scholar
Blumenschein G. Jr., Sorafenib in lung cancer: clinical developments and future directions. J Thorac Oncol. 2008;3:S124–7.
Google Scholar
Brunet L, Alexandre D, Lee J, Blanquer-Rossello MDM, Bracquemond D, Guernet A, et al. Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells. Nat Commun. 2025;16:7853.
Google Scholar
Dingemans AM, Mellema WW, Groen HJ, van Wijk A, Burgers SA, Kunst PW, et al. A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation. Clin Cancer Res. 2013;19:743–51.
Google Scholar
Paz-Ares L, Hirsh V, Zhang L, de Marinis F, Yang JC, Wakelee HA, et al. Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in patients with relapsed or refractory predominantly nonsquamous non-small-cell lung cancer after 2 or 3 previous treatment regimens. J Thorac Oncol. 2015;10:1745–53.
Google Scholar
Vejzovic D, Kubin A, Fechter K, Karner C, Hartmann J, Ackerbauer T, et al. Glioblastoma targeting by water-soluble hypericin derivate HHL-PVP and photodynamic tumour killing. Biomed Pharmacother. 2025;186:118041.
Google Scholar
Liang C, Liu X, Yu J, Shi L, Wei W, Zhu Y, et al. Hypericin photoactivation induces triple-negative breast cancer cells pyroptosis by targeting the ROS/CALR/Caspase-3/GSDME pathway. J Adv Res. 2025;77:669–88.
Google Scholar
Piryaei M, Mehrparvar B, Mohammadian A, Shahriari F, Javidi MA. Anti-cancer impact of Hypericin in B-CPAP cells: Extrinsic caspase dependent apoptosis induction and metastasis obstruction. Eur J Pharm. 2021;910:174454.
Google Scholar
Vargova J, Mikes J, Jendzelovsky R, Mikesova L, Kucharova B, Culka L, et al. Hypericin affects cancer side populations via competitive inhibition of BCRP. Biomed Pharmacother. 2018;99:511–22.
Google Scholar
Hu J, Song J, Tang Z, Wei S, Chen L, Zhou R. Hypericin-mediated photodynamic therapy inhibits growth of colorectal cancer cells via inducing S phase cell cycle arrest and apoptosis. Eur J Pharm. 2021;900:174071.
Google Scholar
Drosten M, Barbacid M. Targeting the MAPK pathway in KRAS-driven tumors. Cancer Cell. 2020;37:543–50.
Google Scholar
Timar J, Kashofer K. Molecular epidemiology and diagnostics of KRAS mutations in human cancer. Cancer Metastas Rev. 2020;39:1029–38.
Google Scholar
Rosell R, Aguilar A, Pedraz C, Chaib I. KRAS inhibitors, approved. Nat Cancer. 2021;2:1254–6.
Google Scholar
Sattler M, Mohanty A, Kulkarni P, Salgia R. Precision oncology provides opportunities for targeting KRAS-inhibitor resistance. Trends Cancer. 2023;9:42–54.
Google Scholar
Singhal A, Li BT, O’Reilly EM. Targeting KRAS in cancer. Nat Med. 2024;30:969–83.
Google Scholar
Tan AC, Tan DSW. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol. 2022;40:611–25.
Google Scholar
Roskoski R, Jr. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. Pharmacol Res. 135, 239–58.
Choucair K, Imtiaz H, Uddin MH, Nagasaka MN, Al-Hallak MN, Philip PA et al. Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges. Signal transduction and targeted therapy. 10, 385.
Wang K, Zhang X, Fan Y, Zhou L, Duan Y, Li S et al. Reactivation of MAPK-SOX2 pathway confers ferroptosis sensitivity in KRASG12C inhibitor-resistant tumors. Redox Biol 78, 103419.
Ding M, Shi R, Cheng S, Li M, De D, Liu C, et al. Mfn2-mediated mitochondrial fusion alleviates doxorubicin-induced cardiotoxicity with enhancing its anticancer activity through metabolic switch. Redox Biol. 2022;52:102311.
Google Scholar
Qian L, Fu Z, Chen P, Guo Y, Li Y, Wang Y, et al. Lysophosphatidic acid-induced Arf6-driven macropinocytosis of CD147+ extracellular vesicles promotes sorafenib resistance of hepatocellular carcinoma. Int J Biol Sci. 22, 220–38.
Qian L, Chen P, Wang B, Zhang Q, Guo Y, Cui J et al. CD147-positive migrasome macropinocytosis promotes HCC sorafenib resistance via inducing vasculogenic mimicry triggered by PI3K/AKT/TWIST1 signaling. Cell Death Dis https://doi.org/10.1038/s41419-026-08972-y.
Huang C, Min Y, Liu J, Li J, Yang X. Ring finger protein 126: a potential biomarker for colorectal cancer. Histol Histopathol. 2021;36:559–66.
Google Scholar
Tian H, Zhao D, Zhou Z, Kim A, Huang H, Lee YJ, et al. SRC at the crossroads of KRAS inhibitor resistance: Mechanisms and therapeutic opportunities. Cancer Lett. 639: 218194.
Li H, Sun L, Gao P, Hu H. Lactylation in cancer: Current understanding and challenges. Cancer Cell. 2024;42:1803–7.
Google Scholar
Iozzo M, Pardella E, Giannoni E, Chiarugi P. The role of protein lactylation: A kaleidoscopic post-translational modification in cancer. Mol Cell. 2025;85:1263–79.
Google Scholar
Sheng X, Lin H, Cole PA, Zhao Y. Biochemistry and regulation of histone lysine L-lactylation. Nat Rev Mol Cell Biol. 2026;27:95–109.
Google Scholar
Yan L, Wang Y, Hu H, Yang D, Wang W, Luo Z, et al. Physical exercise mediates cortical synaptic protein lactylation to improve stress resilience. Cell Metab. 2024;36:2104–17 e4.
Google Scholar
Zhang C, Zhou L, Zhang M, Du Y, Li C, Ren H, et al. H3K18 Lactylation Potentiates Immune Escape of Non-Small Cell Lung Cancer. Cancer Res. 2024;84:3589–601.
Google Scholar
Yang C, Yang R, Zheng B, Jiang H, Wang X, Huang W. Lactylation as a metabolic-epigenetic switch in cancer: dual roles in cell death resistance and therapeutic vulnerability. Cell Death Dis. 17, 298.
Polletta L, Vernucci E, Carnevale I, Arcangeli T, Rotili D, Palmerio S, et al. SIRT5 regulation of ammonia-induced autophagy and mitophagy. Autophagy. 2015;11:253–70.
Google Scholar
Li J, Xun W, Wang X, Luo R, Hu Q, Zhou Z, et al. Lactylation enhances the activity of lactate Dehydrogenase A and promotes chemoresistance to cisplatin through facilitating DNA nonhomologous end junction in lung Adenocarcinoma. Adv Sci. 13, e10733.
Zeng T, Q Wang, L Li, X Tan, J He, Y Liu, et al. ENO1 lactylation drives bevacizumab resistance through metabolic reprogramming and angiogenesis in ovarian cancer. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy. 87, 101413.
Chen H, Li Y, Li H, Chen X, Fu H, Mao D, et al. NBS1 lactylation is required for efficient DNA repair and chemotherapy resistance. Nature. 2024;631:663–9.
Google Scholar
Du Y, He M, Xu Y, Tian T, Zhou Y, Zhang Y, et al. AARS1-mediated lactylation of STAT1 drives immune evasion. Cell Rep. 2026;45:117094.
Google Scholar
Lin J, Yin Y, Cao J, Zhang Y, Chen J, Chen R, et al. NUDT21 lactylation reprograms alternative polyadenylation to promote cuproptosis resistance. Cell Discov. 2025;11:52.
Google Scholar
Xing Z, Yang T, Li X, Xu H, Hong Y, Shao S, et al. High-glucose-associated YTHDC1 lactylation reduces the sensitivity of bladder cancer to enfortumab vedotin therapy. Cell Rep. 2025;44:115545.
Google Scholar
Liu H, Ge B. Lactylation as a post-translational regulator of cGAS and immunity. Mol Cell. 2024;84:4483–5.
Google Scholar
Yu H, Yin H, Mei Y, Bai X, Zhang C, Feng Z, et al. Nucleophosmin 1 lactylation in graft kidney induces ferroptotic trigger waves that exacerbate delayed graft function. Nat Commun. 2025;17:277.
Google Scholar
Pranzini E, Pardella E, Paoli P, Fendt SM, Taddei ML. Metabolic reprogramming in anticancer drug resistance: a focus on amino acids. Trends Cancer. 2021;7:682–99.
Google Scholar
Ye WL, Huang L, Yang XQ, Wan S, Gan WJ, Yang Y, et al. TRIM21 induces selective autophagic degradation of c-Myc and sensitizes regorafenib therapy in colorectal cancer. Proc Natl Acad Sci USA. 2024;121:e2406936121.
Google Scholar
Li XM, Yang Y, Jiang FQ, Hu G, Wan S, Yan WY, et al. Histone lactylation inhibits RARgamma expression in macrophages to promote colorectal tumorigenesis through activation of TRAF6-IL-6-STAT3 signaling. Cell Rep. 2024;43:113688.
Google Scholar
Liu Y, Kimpara S, Hoang NM, Daenthanasanmak A, Li Y, Lu L, et al. EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B-cell lymphoma. Blood. 2023;142:1879–94.
Google Scholar
Tan Y, Li J, Zhao G, Huang KC, Cardenas H, Wang Y, et al. Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells. Nat Commun. 2022;13:4554.
Google Scholar
Hu W, Yang J, Chen Z, Li Y, Luo G, Hu K, et al. SLC25A39 overexpression exacerbates lung adenocarcinoma progression and is negatively regulated by AFG3L2. NPJ Precis Oncol. 2025;9:317.
Google Scholar
Chen Z, Yang J, Zhang Q, Zeng W, Liu Y, Hu W, et al. Inhalable myofibroblast targeting nanoparticles for synergistic treatment of pulmonary fibrosis. Sci Adv. 2025;11:eadv9571.
Google Scholar
Wang Y, Liu F, Wu J, Zhang MQ, Chai JL, Cao C. G protein inhibitory alpha subunit 2 is a molecular oncotarget of human glioma. Int J Biol Sci. 2023;19:865–79.
Google Scholar
Yao J, Wu XY, Yu Q, Yang SF, Yuan J, Zhang ZQ, et al. The requirement of phosphoenolpyruvate carboxykinase 1 for angiogenesis in vitro and in vivo. Sci Adv. 2022;8:eabn6928.
Google Scholar
Yang J, Chen Z, Hu W, Zeng W, Lei Z, Tong X, et al. Acetylation-dependent USP7-TRIM25 axis drives oncogenic progression in non-small cell lung cancer. Cell Death Dis. 2025;16:695.
Google Scholar
